Highlights:
1. BIOALVO, a global biotech company acting on the early stages of drug discovery and development with headquarters in Lisbon, Portugal, offers a Post-Doctoral Position within the scope of the FP7-funded project entitled “α-synuclein and Tau: dangerous liaisons”.
2. Although classically considered as distinct pathological entities, recent emerging evidence is revealing a number of pathological and clinical features with consistent overlapping between synucleinopathies and tauopathies, suggesting a mechanistic link between these disorders. The project is to clarify the synergistic effect of α-synuclein and tau interaction in the neurodegenerative process and to identify compounds that modulate that synergy.
3. We will take advantage of the power of yeast genetics in order to perform a genome wide screening to identify genes that modulate the toxic phenotype caused by the concomitant expression of tau and α-synuclein. We want to identify cellular targets of future therapeutic intervention in order to generate a yeast-based drug discovery platform for the screening of compounds with the potential to ameliorate diseases associated with tau and/or synuclein.